Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Immupharma (IMM) Share News

1234567

IN BRIEF: ImmuPharma rises on FDA feedback for neurological disease

18th May 2023 12:12

ImmuPharma PLC - London-based drug discovery and development company - Gets positive support and guidance from the US Food & Drug Administration after a pre-investigational new drug meeting, which confirms the route for a Phase 2/3 adaptive clinical study of P140 in chronic idiopathic demyelinating polyneuropathy. Says the feedback recognises that P140 is suitable to be studied in another disease indication, in addition to systemic lupus erythematosus. Read More

IN BRIEF: ImmuPharma annual loss narrows as R&D spending reduced

11th May 2023 11:48

ImmuPharma PLC - London-based drug discovery and development company - Posts no revenue for 2022, compared to GBP118,350 for 2021. Pretax loss narrows to GBP4.5 million from GBP8.9 million a year earlier, as operating loss reduces to GBP3.0 million from GBP6.6 million. Research and development expenditure is GBP2.0 million, down from GBP3.7 million in 2021. Chief Executive Officer Tim McCarthy says: "As a board, we remain focused on bringing our two key late stage clinical assets, Lupuzor for lupus and CIDP closer to the market." Read More

IN BRIEF: ImmuPharma says US FDA confirms date for Lupuzor meeting

19th Apr 2023 15:40

ImmuPharma PLC - London-based drug discovery and development company - Notes the US Food & Drug Administration has set a date of June 7 for a type-C meeting to provide guidance on the phase 2/3 adaptive study of Lupuzor, or P140, in patients with systemic lupus erythematosus, a common type of immune disease lupus. Says this follows the announcement in late March, when it submitted a phase 2/3 clinical trial protocol to the US FDA testing the Lupuzor treatment for lupus patients. Read More

IN BRIEF: ImmuPharma shares up as FDA meeting for new drug confirmed

12th Apr 2023 11:27

ImmuPharma PLC - London-based drug discovery and development company - Gets confirmation of a pre-investigational new drug meeting with the US Food & Drug Administration, which will take place on May 16. It concerns the phase 2/3 adaptive trial study protocol for P140 in chronic idiopathic demyelinating polyneuropathy. Says the CIDP market is expected to reach global sales of USD2.7 billion by 2029. CIDP is a rare acquired autoimmune disorder of peripheral nerve affecting about 50,000 individuals across the US and Europe. Read More

AIM WINNERS & LOSERS: System1 rises after upturn in second half

12th Apr 2023 10:37

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday. Read More

LONDON MARKET OPEN: Stocks looking for direction before US inflation

12th Apr 2023 08:49

(Alliance News) - Stock prices in London opened mixed on Wednesday, as caution prevailed ahead of a US inflation reading and minutes from the Federal Reserve's March meeting. Read More

LONDON MARKET MIDDAY: Bank stocks get boost as SVB assets bought

27th Mar 2023 12:05

(Alliance News) - Stock prices in London were higher at midday on Monday, as investor sentiment was lifted by the news that a US bank will buy more USD70 billion dollars of Silicon Valley Bank assets. Read More

AIM WINNERS & LOSERS: ScotGold drops two-thirds as gold grade declines

27th Mar 2023 10:51

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More

ImmuPharma submits phase 2/3 protocol to US FDA for Lupuzor treatment

27th Mar 2023 10:32

(Alliance News) - ImmuPharma PLC on Monday said it submitted a phase 2/3 clinical trial protocol to the US Food & Drug Administration testing the Lupuzor treatment for lupus patients. Read More

ImmuPharma signs 12-month deal with Orano for use of peptide tech

6th Mar 2023 11:22

(Alliance News) - ImmuPharma PLC on Monday said it has signed an initial collaboration agreement with Orano SA for its peptide technology. Read More

ImmuPharma agrees study design with Avion for lupus programme Lupuzor

6th Feb 2023 11:37

(Alliance News) - ImmuPharma PLC on Monday confirmed alongside its partner Avion Pharmaceuticals that a phase 2/3 adaptive trial will be the best design for the next clinical study of Lupuzor in systemic lupus erythematosus patients. Read More

TRADING UPDATES: Ground Rents Income Fund's portfolio value drops

22nd Dec 2022 21:09

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

TRADING UPDATES: Driver records loss; Synectics sells business unit

11th Nov 2022 19:56

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

TRADING UPDATES: ImmuPharma loss narrows; MetalNRG loss widens

6th Oct 2022 20:10

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

UK earnings, trading statements calendar - next 7 days

23rd Sep 2022 15:56

Read More

IN BRIEF: ImmuPharma receives response for FDA for Lupuzor

14th Sep 2022 12:46

ImmuPharma PLC - specialist drug discovery and development company - Says its US partner for Lupuzor, Avion Pharmaceuticals LLC, has received a written response from the US Food & Drug Administration that provided detailed guidance on the next steps for the drug's clinical programme. This included advice on the dosing regime, as well as guidance on the study protocol that can be amended to improve the regulatory outcome. Read More

ImmuPharma raises GBP150,000 via issue of 3 million new shares

7th Sep 2022 09:55

ImmuPharma PLC - specialist drug discovery and development company - Says L1 Capital Global Opportunities Master Fund has exercised options over 3.0 million new shares at a price of 5 pence each, for GBP150,000 in total. The new shares represent 0.9% of the company's enlarged share capital. Read More

TRADING UPDATES: ImmuPharma waits on FDA; IDE Group waits on audit

31st Aug 2022 21:41

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

IN BRIEF: ImmuPharma raises GBP950,000 from broker option

11th Aug 2022 19:08

ImmuPharma PLC - specialist drug discovery and development company - Raises GBP950,000 under broker option, taking total proceeds from placing and broker option to GBP1.04 million. "Further to the announcement of August 3, 2022, the directors confirm that the fundraising, together with existing funding and funding arrangements, will provide the company with sufficient working capital for at least the next 12 months," it says. Read More

IN BRIEF: ImmuPharma to raise funds for investment into pipeline

3rd Aug 2022 19:40

ImmuPharma PLC - specialist drug discovery and development company - Intends to raise GBP1.1 million through the placing and subscription of 21.8 million shares at a price of 5.0 pence per share. Read More

1234567
FTSE 100 Latest
Value8,809.74
Change53.53